Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 2/2009

Open Access 01-02-2009 | Gastrointestinal Oncology

Expression of Receptor for Advanced Glycation End Products (RAGE) is Related to Prognosis in Patients with Esophageal Squamous Cell Carcinoma

Authors: Taro Tateno, MD, Shinichi Ueno, MD, PhD, Kiyokazu Hiwatashi, MD, PhD, Masataka Matsumoto, MD, PhD, Hiroshi Okumura, MD, PhD, Tetsuro Setoyama, MD, PhD, Yasuto Uchikado, MD, PhD, Masahiko Sakoda, MD, PhD, Fumitake Kubo, MD, PhD, Sumiya Ishigami, MD, PhD, Hiroyuki Shinchi, MD, PhD, Shoji Natsugoe, MD, PhD

Published in: Annals of Surgical Oncology | Issue 2/2009

Login to get access

Abstract

The receptor for advanced glycation end products (RAGE), known as a multiligand receptor for certain stress-associated factors, has been considered to affect the characteristic differences of various cancer cells. We analyzed the expression and clinicopathological significance of RAGE in esophageal squamous cell carcinoma. We investigated immunohistochemically the relationship between RAGE expression and clinicopathological factors, including prognosis, in surgical specimens of primary tumors in 216 patients with esophageal squamous cell carcinoma. Prognostic factors were examined by univariate and multivariate analyses (Cox proportional hazard regression model). The positive expression rate of RAGE was 50%. RAGE expression was negatively correlated with depth of invasion and venous invasion. Moreover, tumors with positive RAGE expression exhibited better prognosis than those with negative RAGE expression (5-year survival, 52% vs. 32%, respectively). Multivariate analysis indicated that the positive expression of RAGE was an independent prognostic factor, along with tumor depth and nodal metastasis. Our findings suggest that loss of RAGE expression may play an important role in the progression of esophageal squamous cell carcinoma. Evaluation of the expression of RAGE could be useful for determining the tumor properties, including those associated with prognosis, in patients with esophageal squamous cell carcinoma.
Literature
1.
Rauvala H, Pihlaskari R. Isolation and some characteristics of an adhesive factor of brain that enhances neurite outgrowth in central neurons. J Biol Chem. 1987;262:16625–35.PubMed
2.
Hofmann MA, Drury S, Fu C, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999;97:889–901.PubMedCrossRef
3.
Du Yan S, Zhu H, Fu J, et al. Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci USA. 1997;94:5296–301.PubMedCrossRef
4.
Yeh CH, Sturgis L, Haidacher J, et al. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes. 2001;50:1495–504.PubMedCrossRef
5.
Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem. 1999;274:19919–24.PubMedCrossRef
6.
Wautier MP, Chappey O, Corda S, et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab. 2001;280:E685–94.PubMed
7.
Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285:248–51.PubMedCrossRef
8.
Yamamoto Y, Kato I, Doi T, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest. 2001;108:261–8.PubMed
9.
Liliensiek B, Weigand MA, Bierhaus A, et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest. 2004;113:1641–50.PubMed
10.
Taguchi A, Blood DC, del Toro G, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature. 2000;405:354–60.PubMedCrossRef
11.
Kuniyasu H, Oue N, Wakikawa A, et al. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol. 2002;196:163–70.PubMedCrossRef
12.
Kuniyasu H, Chihara Y, Kondo H. Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Int J Cancer. 2003;104:722–7.PubMedCrossRef
13.
Kuniyasu H, Chihara Y, Takahashi T. Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep. 2003;10:445–8.PubMed
14.
Hirata K, Takada M, Suzuki Y, et al. Expression of receptor for advanced glycation end products (RAGE) in human biliary cancer cells. Hepatogastroenterology. 2003;50:1205–7.PubMed
15.
Takada M, Koizumi T, Toyama H, et al. Differential expression of RAGE in human pancreatic carcinoma cells. Hepatogastroenterology. 2001;48:1577–8.PubMed
16.
Ishiguro H, Nakaigawa N, Miyoshi Y, et al. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate. 2005;64:92–100.PubMedCrossRef
17.
Bartling B, Hofmann HS, Weigle B, et al. Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non–small cell lung carcinoma. Carcinogenesis. 2005;26:293–301.PubMedCrossRef
18.
Landesberg R, Woo V, Huang L, et al. The expression of the receptor for glycation endproducts (RAGE) in oral squamous cell carcinomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;105:617–24.PubMedCrossRef
19.
Riuzzi F, Sorci G, Donato R. RAGE expression in rhabdomyosarcoma cells results in myogenic differentiation and reduced proliferation, migration, invasiveness, and tumor growth. Am J Pathol. 2007;171:947–61.PubMedCrossRef
20.
Hiwatashi K, Ueno S, Abeyama K, et al. A novel function of the receptor for advanced glycation end-products (RAGE) in association with tumorigenesis and tumor differentiation of HCC. Ann Surg Oncol. 2008;15:923–33.PubMedCrossRef
21.
Sobin LH, Fleming ID. TNM classification of malignant tumors, 5th ed. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 1997;80:1803–4.PubMedCrossRef
22.
Pileri SA, Roncador G, Ceccarelli C, et al. Antigen retrieval techniques in immunohistochemistry: comparison of different methods. J Pathol. 1997;183:116–23.PubMedCrossRef
23.
Huttunen HJ, Fages C, Kuja-Panula J, et al. Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res. 2002;62:4805–11.PubMed
24.
Riuzzi F, Sorci G, Donato R. The amphoterin (HMGB1)/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness. Functional inactivation of RAGE in L6 myoblasts results in tumor formation in vivo. J Biol Chem. 2006;281:8242–53.
25.
Sasahira T, Akama Y, Fujii K, et al. Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas. Virchows Arch. 2005;446:411–5.PubMedCrossRef
26.
Sajithlal G, Huttunen H, Rauvala H, et al. Receptor for advanced glycation end products plays a more important role in cellular survival than in neurite outgrowth during retinoic acid-induced differentiation of neuroblastoma cells. J Biol Chem. 2002;277:6888–97.PubMedCrossRef
27.
Sorci G, Riuzzi F, Arcuri C, et al. Amphoterin stimulates myogenesis and counteracts the antimyogenic factors basic fibroblast growth factor and S100B via RAGE binding. Mol Cell Biol. 2004;24:4880–94.PubMedCrossRef
28.
Uchikado Y, Natsugoe S, Okumura H, et al. Slug expression in the E-cadherin preserved tumors is related to prognosis in patients with esophageal squamous cell carcinoma. Clin Cancer Res. 2005;11:1174–80.PubMed
29.
Nagafuchi A, Shirayoshi Y, Okazaki K, et al. Transformation of cell adhesion properties by exogenously introduced E-cadherin cDNA. Nature. 1987;329:341–3.PubMedCrossRef
Metadata
Title
Expression of Receptor for Advanced Glycation End Products (RAGE) is Related to Prognosis in Patients with Esophageal Squamous Cell Carcinoma
Authors
Taro Tateno, MD
Shinichi Ueno, MD, PhD
Kiyokazu Hiwatashi, MD, PhD
Masataka Matsumoto, MD, PhD
Hiroshi Okumura, MD, PhD
Tetsuro Setoyama, MD, PhD
Yasuto Uchikado, MD, PhD
Masahiko Sakoda, MD, PhD
Fumitake Kubo, MD, PhD
Sumiya Ishigami, MD, PhD
Hiroyuki Shinchi, MD, PhD
Shoji Natsugoe, MD, PhD
Publication date
01-02-2009
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 2/2009
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-008-0237-z

Other articles of this Issue 2/2009

Annals of Surgical Oncology 2/2009 Go to the issue

Gynecologic Oncology

The Use of Sodium Hyaluronate–Carboxymethylcellulose (HA-CMC) Barrier in Gynecologic Malignancies: A Retrospective Review of Outcomes

Hepatobiliary and Pancreatic Tumors

Induction of Tumor Growth After Preoperative Portal Vein Embolization: Is It a Real Problem?

Bone and Soft Tissue Sarcomas

Diffuse Malignant Peritoneal Mesothelioma: Failure Analysis Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Hepatobiliary and Pancreatic Tumors

Immunohistochemically Detected Expression of p27Kip1 and Skp2 Predicts Survival in Patients with Intrahepatic Cholangiocarcinomas

Breast Oncology

Predicting and Preventing Positive Surgical Margins and Local Failures in Breast-Conserving Surgery

Healthcare Policy and Outcomes

Undertreatment of Tracheal Carcinoma: Multidisciplinary Audit of Epidemiologic Data